Dynavax Technologies Corporation (DVAX:NASDAQ) closed at $15.50 on February 10, 2026, unchanged on the day. Dynavax Technologies Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, DVAX closed higher on 35 days (14%). Its best day was December 24, 2025 (+38.19%) and its worst was December 1, 2025 (-5.80%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix...
Find more stocks like DVAX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.